血液腫瘤科 - 中國醫藥大學附設醫院

科室介紹

血液腫瘤科

:::

血液腫瘤科/

期刊論文

目前搜尋條件：「血液腫瘤科」 - 「期刊論文」 -

Time

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

$INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer$

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer

Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer

Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.

Silmitasertib Plus Gemcitabine and Cisplatin First-Line Therapy in Locally Advanced/Metastatic Cholangiocarcinoma: a Phase 1b/2 Study

Silmitasertib Plus Gemcitabine and Cisplatin First-Line Therapy in Locally Advanced/Metastatic Cholangiocarcinoma: a Phase 1b/2 Study

Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial

Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial

s

側邊開關圖示

中國醫點通

百度搜狗 360搜索念无双平安保险公司灵灵拒保小米su7车主: 不好意思，渠道有限制，无法续保！！！尹锡悦或面临多项指控刑期或创新高卡位Power rack，麦格米特再迎超300亿的增量空间？丨智氪解放军台海作战不怕打明牌

<code id='d689b'></code><style id='93083'></style>

<acronym id='5efea'></acronym>

<center id='551c5'><center id='e4020'><tfoot id='87663'></tfoot></center><abbr id='5bfe4'><dir id='a3b6a'><tfoot id='b4154'></tfoot><noframes id='1cec9'>

<optgroup id='916d6'><strike id='198f9'><sup id='dde74'></sup></strike><code id='90685'></code></optgroup>

<b id='0361f'><label id='bc87e'><select id='fedf1'><dt id='7c518'><span id='64fbe'></span></dt></select></label></b><u id='cc52e'></u>

~~<i id='8feca'><strike id='61460'><tt id='a2c7e'><pre id='a8704'></pre></tt></strike></i>~~